Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02797665

Enrollment

Registered

2016-06-13

Start date

2016-05-31

Completion date

2021-12-31

Last updated

2020-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis, Obstructive Jaundice

Brief summary

This study evaluates corticosteroids in the treatment of obstructive jaundice in autoimmune pancreatitis and/or immunoglobulin G4 (IgG4)-related sclerosing cholangitis in adults. Half of participants will receive corticosteroids alone, while the other half will receive corticosteroids with biliary stent at the beginning.

Interventions

DRUGcorticosteroids

prednisone 0.6mg/kg/d

PROCEDUREbiliary stent

placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adults greater than 18 years-old; * autoimmune pancreatitis and/or IgG4-related sclerosing cholangitis; * obstructive jaundice

Exclusion criteria

* malignancies; active infections; * pregnancy or breast feeding; * standard contraindications to ERCP; * unwillingness or inability to consent for the study

Design outcomes

Primary

Measure	Time frame
Clinical remission rate of obstructive jaundice	Day 60

Countries

China

Contacts

Primary ContactAiming Yang, M.D.

yangaiming@medmail.com.cn+86-10-69151593

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026